NS 2330 is a dopamine re-uptake inhibitor. A dopamine re-uptake inhibitor basically keeps dopamine functioning in a person's brain for a longer period of time. In the science of brain chemicals, the neurotransmitter dopamine is released from one neuron and travels to another neuron as part of a motion message, or even an emotion message. After the dopamine has made its delivery between the neurons, it is frequently reabsorbed by the neuron that sent it out. That is called re-uptake. After re-uptake, the neuron often deems the dopamine molecule worn-out and starts to break it down.
You have probably heard of some common dopamine re-uptake inhibitors. Some of the most famous or infamous include:
- Methylphenidate (Ritalin)
- Bupropion (Wellbutrin, Zyban)
- Methamphetamine
- Cocaine
Some of these chemicals have a lot of medical potential, but at the same time, you would never think of prescribing an illicit dopamine re-uptake inhibitor. However, if a substance could stop dopamine from going through the re-uptake process, more dopamine would circulate in the brain to send messages. With NS 2330 providing more dopamine, scientists hoped Parkinson's symptoms would subside. However, it did not live up to the expectation.
With any experimental drug, the odds of it succeeding (making it to market) are roughly 10 percent. Perhaps another dopamine re-uptake inhibitor will be more effective in the future.
